277 related articles for article (PubMed ID: 10348265)
21. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
22. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
23. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.
Verstappen CC; Postma TJ; Geldof AA; Heimans JJ
Anticancer Res; 2004; 24(4):2337-41. PubMed ID: 15330181
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of amifostine: effects of dose and method of administration.
Shaw LM; Bonner HS; Schuchter L; Schiller J; Lieberman R
Semin Oncol; 1999 Apr; 26(2 Suppl 7):34-6. PubMed ID: 10348258
[TBL] [Abstract][Full Text] [Related]
25. Amifostine modulation of bleomycin-induced lung injury in rodents.
Nici L; Calabresi P
Semin Oncol; 1999 Apr; 26(2 Suppl 7):28-33. PubMed ID: 10348257
[TBL] [Abstract][Full Text] [Related]
26. Future development of amifostine in cancer treatment.
Alberts DS; Bleyer WA
Semin Oncol; 1996 Aug; 23(4 Suppl 8):90-9. PubMed ID: 8783674
[TBL] [Abstract][Full Text] [Related]
27. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
28. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapeutic studies with amifostine (Ethyol).
Wasserman TH
Semin Oncol; 1994 Oct; 21(5 Suppl 11):21-5. PubMed ID: 7973775
[TBL] [Abstract][Full Text] [Related]
30. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
31. Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Viele CS; Holmes BC
Oncol Nurs Forum; 1998 Apr; 25(3):515-23. PubMed ID: 9568606
[TBL] [Abstract][Full Text] [Related]
32. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
List AF
Semin Oncol; 1999 Apr; 26(2 Suppl 7):61-5. PubMed ID: 10348262
[TBL] [Abstract][Full Text] [Related]
33. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
34. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
35. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
[No Abstract] [Full Text] [Related]
36. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
37. Radioprotectants: pharmacology and clinical applications of amifostine.
Dorr RT
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
[TBL] [Abstract][Full Text] [Related]
38. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
39. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
40. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
